Hyperphosphatemia Market Accelerates Towards US$ 20.24 Billion with a 4.8% CAGR Through 2033 | Report By Future Market Insights

Future Market Insights projects that between 2023 and 2033, the hyperphosphatemia market would grow rapidly. The global market for pharmaceuticals treating hyperphosphatemia is predicted to expand at a similar rate by 2033, when sales of these drugs are projected to reach US$ 20.24 billion.

Various calcium-based phosphorus binders are being used in the present day as calcium supplements and can replace aluminum-based phosphorus binders. The development of new treatment therapies for hyperphosphatemia is being pursued across the globe by companies. Future generations will benefit from emerging treatments that will transform treatment dynamics. Market trends are shifting towards non-phosphate binders. Additionally, new products are being introduced in developing countries to propel hyperphosphatemia market growth.

Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16234

A majority of dialysis patients with hyperphosphatemia are treated with phosphate binders, according to the National Center for Biotechnology Information (NCBI). The prevalence of chronic renal diseases is expected to significantly support the market’s growth over the forecast period. With China’s central government focusing on robust growth initiatives, it is predicted that demand for hyperphosphatemia medications will increase due to the country’s expanding healthcare infrastructure.

As chronic diseases become more prevalent in the population, the market for hyperphosphatemia treatment is expected to increase. ESRD patients with hyperphosphatemia have been more likely to need treatment for hyperphosphatemia, so the demand for hyperphosphatemia drugs or treatment has increased.

Key Takeaways:

• The global hyperphosphatemia market is expected to reach US$ 20.24 billion by 2033, growing at a CAGR of 4.8%.
• Iron-based phosphate binder is expected to grab 20% of the hyperphosphatemia market by 2023.
• North America accounted for 36% of the worldwide revenue generated by hyperphosphatemia in 2023.
• According to predictions for 2023, Europe will hold 25% of the global market.
• With more than 8% market share, the low serum calcium level test is the most popular test type for the hyperphosphatemia market.

“Researchers are studying more and more new drugs and therapies. In recent years, at-home test kits have gained popularity. A generics reimbursement program will reduce coverage for expensive therapies, says an analyst at FMI.

Competitive Landscape

As companies with a wide geographic reach look to expand their product offering and develop more complex applications, they are taking collaborative steps to boost sales, from acquiring other businesses into their own to creating a more flexible medical system.

Strategic, profitable partnerships are helping competitors consolidate their market presence. By acquiring and partnering with companies, advanced technology can be used more effectively. Several deals are entered into by home health kits in order to expand their technology horizons.

• Biopharmaceutical company Ardelyx, Inc., founded to find, develop and commercialize innovative first-in-class medicines to address significant unmet medical needs, announced that three posters will be presented during Kidney Week 2022, which will be held in Orlando, Florida, from November 3-6, 2022. A phosphate absorption inhibitor (PAI) developed and discovered by Ardelyx for treating chronic kidney disease (CKD) suffering from dialysis patients is XPHOZAH (tenapanor).
• The RENAZORB bioequivalence (BE) study has concluded enrollment at Unicycive Therapeutics, a clinical-stage biotechnology company. Research is being conducted to develop RENAZORB (lanthanum dioxycarbonate) to treat hyperphosphatemia in kidney dialysis patients with chronic kidney disease.

More Valuable Insights Available

Future Market Insights, in its new offering, presents an unbiased analysis of the hyperphosphatemia market, presenting historical demand data (2018-2022) and forecast statistics for the period of 2023-2033.

The study divulges essential insights into the hyperphosphatemia market analysis report drug class (calcium based phosphate binders, iron-based phosphate binders, lanthanum carbonate, non-phosphate binders) by test type (low serum calcium level type, blood urea nitrogen test, phosphate level test, creatinine value test), by end user (hospitals, ambulatory surgical centers, specialty clinics, others), and by region (North America, Latin America, Western Europe, Eastern Europe, APAC and MEA).

Unleash Potential: Craft Your Customized Report Now:
https://www.futuremarketinsights.com/customization-available/rep-gb-16234

About the Healthcare Division at Future Market Insights

Our healthcare consulting team guides organizations at each step of their business strategy by helping you understand how the latest influencers account for operational and strategic transformation in the healthcare sector. Our expertise in recognizing the challenges and trends impacting the global healthcare industry provides indispensable insights and support – encasing a strategic perspective that helps you identify critical issues and devise appropriate solutions.

Key Segments Profiled in the Hyperphosphatemia Industry Survey

Hyperphosphatemia Market by Drug Class:

• Calcium Based Phosphate Binders
• Iron Based Phosphate Binders
• Lanthanum Carbonate
• Non Phosphate Binders

Hyperphosphatemia Market by Test Type:

• Low Serum Calcium Level Test
• Blood Urea Nitrogen Test
• Phosphate Level Test
• Creatinine Value Test

Hyperphosphatemia Market by End User:

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Others

Hyperphosphatemia Market by Region:

• North America Hyperphosphatemia Market
• Latin America Hyperphosphatemia Market
• Western Europe Hyperphosphatemia Market
• Eastern Europe Hyperphosphatemia Market
• Asia Pacific Hyperphosphatemia Market
• Middle East & Africa Hyperphosphatemia Market

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube